FDA reviewers question efficacy of Merck's bezlotoxumab

In briefing documents released ahead of an advisory committee meeting to discuss an NDA for bezlotoxumab ( MK-6072) from Merck & Co. Inc. (NYSE:MRK) to prevent recurrences of Clostridium difficle infection, FDA reviewers said there "appears

Read the full 365 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE